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BACKGROUND
Calprotectin is a calcium and zinc binding protein found in the cytosol of neutrophils. It is released at times of cell damage in the gastrointestinal (GI) tract and is resistant to enzymatic degradation allowing for measurement in faecal samples. The faecal calprotectin (FC) test has been shown to correlate well with faecal excretion of 111 indium labeled leucocytes 1 and with both microscopic and endoscopic evidence of GI inflammation 2, 3 . In addition to its use in differentiating irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) [4] [5] [6] [7] [8] , it has been assessed as a marker of mucosal healing [9] [10] [11] [12] . There are seven published studies in adult IBD patients that address the issue of FC as a predictor of clinical relapse with ongoing medical therapy in quiescent Crohn's disease (CD) [13] [14] [15] [16] [17] [18] [19] . Higher FC levels were associated with a greater risk of relapse for those with Ulcerative colitis (UC) [13] [14] [15] [16] [17] , but discrepant results have been seen in CD 14, 15, 19 . Furthermore meta-analysis has shown that there is insufficient evidence to determine whether FC levels in those with ileal CD can serve to predict relapse 20 .
The aim of this study was to prospectively assess the role of FC as a predictive marker of relapse within 12 months in those with asymptomatic CD of all phenotypes.
METHODS

Patients
In this single centre prospective study, 97 consecutive CD patients in clinical remission attending for routine outpatient review between August 2010 and November 2011 were identified and enrolled. Written informed consent was obtained at time of enrollment.
Remission was defined as a Crohn's disease Activity Index (CDAI) 21 of <150 points.
We excluded patients with an unclear diagnosis (ie. 'indeterminate colitis'), clinical relapse within the preceding 3 months, concomitant serious illness, pregnancy, age<18 years, alcohol abuse, non steroidal anti-inflammatory use, and stool culture positivity.
Full ethical approval was awarded on 15 April 2010 by the West of Scotland Research Ethics Service (WeSRES) (REC reference 10/S0704/1).
The first FC sample provided by each participant from our recently published study 22 on the intra-individual variability of FC was used as a baseline value for this prospective follow up study. The samples were collected by the patients at home and processed at the biochemistry laboratory at Glasgow Royal Infirmary. Patients were reviewed at regular 3-6 monthly intervals or at relapse. The primary endpoint was relapse within 12 months, while the secondary endpoint was relapse at any time during follow-up. Relapse was defined as an unplanned escalation in therapy, progression of disease phenotype by the Montreal classification, or hospitalization and/or emergency surgery for active CD.
Biochemistry procedures
The Roche faecal extraction device was used to prepare and analyze stool samples adhering to the manufacturers instructions (Bühlmann calprotectin ELIZA kit). Stool was collected in screw-capped plastic containers and received by laboratory within 48 hours of the final stool collection. Samples were processed by qualified biochemical scientists with Health professionals council registration on site at Glasgow Royal Infirmary. Samples weighing.
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between 98-102 mg were placed into the extraction tube cap, 4.9ml of extraction buffer was then added to all tubes which were recapped and homogenised for 15 minutes on the Alpha multi tube vortexer at maximum speed. The homogenate was centrifuged at 3000rpm for 10 minutes and the supernatants were transferred to plastic tubes and stored at -20 o C. The time from sampling to preparation and freezing was approximately 1 to 3 days. The supernatants were thawed then mixed and centrifuged before analysis with the Bühlmann quantitative calprotectin ELISA kit on the Triturus automated ELISA analyser for determination of calprotectin concentration in stools. Calprotectin was expressed as micrograms per gram (µg/g) of faeces. The faecal samples were stable between 2-8 o C for up to 10 days and faecal extracts for 4 months at -20 o C.
Statistical considerations
The Mann-Whitney or t-test was used, as appropriate, to test for significant differences in continuous variables (including FC) between patients who relapsed by 12 months and those who did not, while Fisher's exact test was used for categorical variables.
The sensitivity and specificity of different FC values to predict relapse by 12 months were calculated for all those who either reached the primary endpoint within 12 months or were followed up for at least 12 months without reaching the primary endpoint, and the resulting receiver operating characteristic (ROC) curve plotted. The corresponding area under the curve (AUC) was calculated to represent the overall predictive power of FC in predicting relapse up to 12 months later. The sensitivity, specificity, and negative and positive predictive values are presented for the FC cutoff value with the optimal balance of sensitivity and specificity. Patients who died or were otherwise lost to follow-up before relapsing or being followed up for 12 months were excluded from this part of the analysis.
The optimal FC cutoff value was subsequently used to calculate Kaplan-Meier (K-M) cumulative event curves of time to relapse for all patients throughout the entire study.
Patients who did not relapse were censored at end of follow-up. A Cox proportional hazards model was fitted to assess the impact of a FC value above or below the chosen cutoff on time to relapse at any point in the study, adjusted for age (in years), gender, any previous surgery (yes/no), and stoma (yes/no).
Sample size calculation
The sample size was calculated for the reliability phase of this study, which is reported in detail elsewhere 22 . Briefly, we estimated that 95 patients would have 80% power to show a 95% confidence interval of total width 0.13 around an intraclass correlation coefficient of 0.9 between the FC values from 3 samples.
RESULTS
The mean age of all 97 recruited patients at baseline was 47 years (SD 16), 38% were male and 20% were smokers. Montreal Classification of CD was as follows: age at diagnosis (A1 8%, A2 71%, A3 21%), location (L1 16%, L2 36%, L3 47%) and behavior (B1 59%, B2 30%, B3 11%, p 15%).
Of 97 patients recruited, the care of three individuals was transferred to another centre, one died of non-IBD related pathology without reaching an endpoint and one was lost to follow up prior to reaching either the primary endpoint or a follow up of 12 months. The sensitivity/specificity part of the analysis therefore included 92 patients.
Of these 92 patients, 10 (10.9%) relapsed within 12 months. Table 1 shows that patients who experienced a relapse within 12 months exhibited higher median FC levels at baseline (414µg/g; IQR 259-590) than those who did not (96 µg/g; IQR 39-237; p=0.005). There were no significant differences in age, gender, surgery, stoma, smoking, age at diagnosis, location, behavior or CRP between those who did and did not relapse by 12 months. Patients were more likely to relapse if they were taking chronic steroids, but very small numbers were on steroids and the difference was only marginally significant. There were no other relationships between drugs and relapse by 12 months. However, while many more patients with FC≥240µg/g did relapse, two-thirds of all patients with FC of or above 240µg/g did not and this is reflected in the low positive predictive value for relapse prediction in our cohort.
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The selected cutoff of 240µg/g was used to produce Kaplan-Meier (K-M) cumulative event curves of time to relapse for all 97 patients and these are presented in Figure 3 . A total of 15 patients relapsed throughout the study. The shortest time to relapse was 87 days and the longest was 560 days (1.5 years), while the remaining 82 patients were followed up for between 98 (3 months) and 849 days (2.3 years) without relapsing. There is a clear separation between the curves, with patients with FCe 240µg/g having a substantially shorter time to relapse than those with FC below the cutoff. Table 2 shows the results of the Cox proportional hazards model of FC on time to relapse adjusted for demographics. The model confirmed the difference in time to relapse between those with high or low FC exhibited in the K-M curves, with a hazard ratio (HR) for FCe 240µg/g vs FC<240µg/g of 5.7 (95% CI 1.9-17.3; p=0.004). Thus, based on our sample, a patient with FCe 240µg/g is around two to 17 times more likely to relapse within about two years than one with FC below 240µg/g. Table 2 also shows that there was no impact of demographics on time to relapse.
As exploratory analyses, the 16 patients with ileal only disease and the 35 patients with colonic only disease were considered separately. Three of the 16 ileal patients relapsed during the study, at 142, 394 and 560 days, with only one having relapsed by 12 months. The three ileal patients who relapsed at any time during the study had higher median baseline FC levels (371 µg/g; IQR 284-741) than the 13 who did not (57 µg/g; IQR 20-101). A Mann Whitney test showed marginal statistical non-significance for this difference (P=0.057). Two of the 35 colonic patients relapsed by 12 months, at 94 and 298 days, with a further two relapsing later at 470 and 524 days. The four colonic patients who relapsed at any time during the study had higher median baseline FC levels (424 µg/g; IQR 209-695) than the 31 who did not (187 µg/g; IQR 48-386), though the difference was not statistically significant (p=0.16).
DISCUSSION
Our prospective dataset, which is the largest yet studied, demonstrates that an FC concentration below 240µg/g is predictive of a low risk of clinical relapse within 12 months for adults with quiescent CD. The ROC curve analysis revealed that the 240µg/g concentration gave an optimal balance of sensitivity (80.0%) and specificity (74.4%).
Despite a reassuringly high negative predictive value of 96.8% at this cut off, the low positive predictive value (27.6%) suggested that FC is most useful as a tool to predict low risk of clinical relapse.
FC is a relatively cheap and non-invasive test making its use attractive in the increasingly financially conscious and risk-averse realm of modern health care. Its use is now established in differentiating irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) [4] [5] [6] [7] [8] .
There is also data supporting its use in evaluating abdominal discomfort 23 , reducing the need for endoscopy in suspected IBD 24 , assessing treatment response in IBD 25, 26 , predicting mucosal healing in IBD 9, 12, [26] [27] , detecting post operative relapse in CD [28] [29] [30] and predicting response to anti-Tumour necrosis factor (anti-TNF) therapy 31-33. We have recently shown that FC levels do not vary considerably within individuals with quiescent CD on a day to day basis 22 . This is reassuring if a one off FC is to be used as a tool to predict future relapse. It would be beneficial for clinicians to target early effective therapies if they could better predict risk. It has been noted that FC may correlate more closely with endoscopic scores than clinical severity scores in CD 34 , hinting at the potential to predict preclinical disease. There are published data on the use of FC levels to predict relapse in UC, which consistently show it to be both sensitive and specific [13] [14] [15] [16] [17] 20 .
There are seven previously published prospective studies that have explored the issue of utilising FC concentrations to predict relapse within a 12 month time period in quiescent adult CD, showing conflicting results [13] [14] [15] [16] [17] [18] [19] . Three studies showed no statistically significant difference between the baseline median FC for relapsers and non-relapsers 14, 15, 19 Conversely, four other studies 13, [16] [17] [18] showed a positive association between FC baseline level and risk of relapse. Tibble and colleagues 13 use a different and older assay but the FC results are equivalent to those of later studies (calprest) when the result is multiplied by a factor of five. They showed in 43 CD patients that relapsing patients had higher median baseline FC compared with that of non-relapsers (122mg/l -which converts to 610µg/g vs 42mg/lwhich converts to 220µg/g). They combined the results with UC patients to produce a receiver operator curve (ROC) curve showing that an equivalent FC concentration of over 250µg/g predicted relapse with a sensitivity of 90% and a specificity of 83%. Garcia-Sanchez et al 17 studied 66 CD patients and identified a best cut off value of 200µg/g (sensitivity 80%, specificity 65%, PPV 46%, and NPV 88%) to predict relapse. They did, however stress that relapse predictability was more accurate for colonic CD. Their PPV and NPV values were similar to our own which suggest greater accuracy for prediction of remission than relapse. In the study by Gisbert et al 16 , a total of 89 CD patients were included, 13 of whom relapsed. FC levels were found to be higher in relapsers (266 vs 145µg/g; P=0.002). Both Gisbert 16 and Garcia-Sanchez 17 drew attention to the fact that a high FC level appeared to be more predictive of relapse in colonic disease. Published commentaries [35] [36] [37] suggested that two of the earlier studies 13, 14 had conflicting results which could be accounted for by differing proportions of small bowel CD patients. Given that greater levels of excreted indium 111labelled leucocytes have been found in colonic vs small bowel CD 38 The ROC curve analysis revealed that a level of >340µg/g provided the maximal sum of sensitivity (80%) and specificity (90.7%) to predict relapse.
More recently, Primas and colleagues 39 Kennedy appear to have identified clinically quiescent patients at baseline as was done in the seven published studies described [13] [14] [15] [16] [17] [18] [19] . The patient populations may therefore not be directly comparable.
Louis et al 41 Our own study shows a positive association between FC level and risk of relapse. Our relapse rate is relatively low at 11% compared with 18.9% in the group studied by Kallel et al 19 and 58% in the study by Tibble et al 13 . Our study, and that by Gisbert et al 16 , included patients on continuing biological therapy which may contribute to their similarly low relapse rate (14.6%). We chose to study all CD phenotypes in an attempt to establish, in a larger cohort, whether an effective cutoff could be determined. Our most effective FC cut off level to predict relapse was shown to be 240µg/g, which is similar to that of Tibble et al 13 but lower than the 340µg/g of Kallel et al 19 . Given that the latter study 19 excluded those without colonic disease and indium 111 leucocytes are excreted in higher levels in colonic disease 38 , this could explain the higher cut off level.
In the meta-analysis by Mao et al 20 , it was commented that there were insufficient available data to determine the use of FC to predict relapse in ileal CD. It is more challenging to assess proximal gastro intestinal inflammation by endoscopy and patients with inflammatory ileal disease may be less likely to have symptoms than those with colonic CD, leading to a greater chance of progressing to fistulising or stricturing disease 43 . Thus, although FC levels tend to be lower in ileal as opposed to colonic disease 38 , the FC test may well have a greater discriminant ability in ileal CD due to the disconnect between clinical symptoms and ileal disease activity in this cohort. Interestingly, we found that the difference in median baseline FC between relapsers and non-relapsers with ileal CD was large and close to statistical significance (371 vs 57µg/g; p=0.057) despite the small number of patients in this subgroup.
It should be noted that these figures were obtained over an extended period of about two years, during which time 3 of the 16 ileal patients had relapsed, since only 1 patient relapsed within 12 months. This result suggests that a larger study, perhaps over a longer time period, of those with ileal CD would be worthwhile to clarify this potential association. In our subgroup of colonic CD, only two of 31 patients relapsed within 12 months and four in the whole study period. Although the mean FC values were higher for the four relapsers (424 vs 187µg/g), statistical significance was not reached (p=0.16).
Although some published articles have shown an association between higher baseline C reactive Protein (CRP) and risk of relapse 18, 42, 43 , others have failed to show this 13, 14, 16 . This study also shows no association between baseline CRP and the risk of subsequent clinical relapse. It should, however, be noted that this study was not designed to detect such an association and approximately half of the patients did not have a baseline CRP measurement.
We did not show an association with relapse and smoking, but the numbers of those smoking at baseline were low (16) and we did not specifically collect data on starting or stopping smoking during the study.
There are additional limitations in our study which merit consideration. Like the previous studies described, we used CDAI rather than endoscopy as an objective assessment of disease activity to define remission. This measure has been shown to correlate poorly with more objective assesments 12 . We would argue however that the risk of endoscopy is not justified for those in remission as it does not reflect current clinical practice. Furthermore, we conducted the study in a tertiary referral institute that may make the findings less applicable to the general population, although no novel therapies are used. The investigators were not blinded to the FC results, but investigators only based treatment decisions on their clinical assessment as there is no prior evidence to change treatment due to FC alone.
In conclusion, our study, utilising the largest prospective dataset in the current literature, provides clearer evidence that adults with quiescent CD with a faecal calprotectin level below 240µg/g are unlikely to relapse within 12 months, while those with a level of 240µg/g or above are substantially more likely to relapse within 12 months. This information can be obtained by non-invasive means and can provide both prognostic information for patient and clinician and a therapeutic target for physicians treating Crohn's patients who are in clinical remission when attending the outpatient clinic.
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FIGURE LEGENDS
Figure 1
Receiver operating characteristic (ROC) curve of the sensitivity and specificity of FC predicting relapse at 12 months for the 93 patients followed up for at least that length of time, based on various cutoffs of FC Figure 2 Scatterplot of the FC values of all patients in the study, with those who relapsed by 12 months marked in red, and those who did not marked in black. The optimal cutoff of 240µg/g marked as a dashed line Figure 3 Kaplan-Meier (K-M) cumulative event curves of time to relapse in days for all patients in the study, stratified by whether their FC was below or above 240µg/g. Patients who did not relapse were censored at end of follow-up and are marked by crosses on the K-M curves
